Abeona Therapeutics Inc. Common Stock (ABEO) Stock Price
ABEOStock
$5.92−13.95%52W
Market Cap$338.53M
P/E5.11x
PEG Ratio—
Div yield—
Beta1.28
ABEO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-2.30%
Price vs S&P 500 (4W)-8.90%
VGM Score39.36
P/E Ratio (Annual)5.11x
ABEO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.24 | -$0.35 | -42.86%(-$0.10) | |
| Q1 2026 | -$0.39 | -$0.30 | +23.73%(+$0.09) | |
| Q4 2025 | -$0.37 | -$0.37 | +2.15%(+$0.01) | |
| Q3 2025 | -$0.34 | -$0.11 | +68.54%(+$0.24) | |
| Q2 2025 | -$0.39 | -$0.47 | -18.96%(-$0.07) |
ABEO Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.33
4.33
4.33
4.33
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABEOAbeona Therapeutics Inc. Common Stock | C | F | C | $5.92 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Abeona Therapeutics Inc. Common Stock
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies and plasma-based treatments for rare genetic diseases with significant unmet medical needs. The company's pipeline includes pz-cel, an autologous cell therapy in development for recessive dystrophic epidermolysis bullosa (RDEB), and adeno-associated virus (AAV)-based gene therapies for rare ophthalmic diseases. These programs target patient populations with limited treatment options and substantial commercial potential.